Accuray shares are trading higher after the company announced the approval of the Tomo C radiation treatment delivery system by China's National Medical Products Administration.
Portfolio Pulse from Benzinga Newsdesk
Accuray has announced that its Tomo C radiation treatment delivery system has been approved by China's National Medical Products Administration. This has led to a rise in the company's share prices.
October 04, 2023 | 4:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Accuray's shares are trading higher following the approval of its Tomo C radiation treatment delivery system by China's National Medical Products Administration.
The approval of Accuray's Tomo C system by China's National Medical Products Administration is a significant milestone for the company. This approval opens up a new market for the company, potentially leading to increased sales and revenues. This positive news has led to an increase in the company's share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100